Search Site
Helpline: 1‑267‑338‑4262 |
AXYS - The Association for X&Y Chromosome Variations
Helpline: 1‑267‑338‑4262 |

Testosterone treatment

Testosterone Early Use – Ross, Davis, 2016

Article Title: Oxandrolone yields short-term benefits in treating Klinefelter’s syndrome

Authors: S.M. Davis, M. Cox-Martin, M. Bardsley, K. Kowal, P.S. Zeitler, and J.L. Ross

Date of Publication: November 14, 2016

” ‘The result of a 2-year, double blind, placebo-controlled trial of oxandrolone in boys with Klinefelter’s syndrome yields modest benefits in some cardiometabolic markers, including percent body fat SDS and fasting triglycerides; however, oxandrolone notably decreased HDL cholesterol and results in mild bone age advancement,’ the researchers wrote. ‘Overall, the short-term cardiometabolic effects of oxandrolone in prepubertal boys with Klinefelter’s syndrome are beneficial; however, additional studies are needed to understand the effect of oxandrolone on long-term cardiometabolic health.’ ”

Read more

Testosterone Early Use – Tartaglia, Rogol, 2010

Article Title: Considerations for Androgen Therapy in Children and Adolescents with Klinefelter Syndrome (47, XXY)

Authors: Nicole Tartaglia MD and Alan Rogol, MD, PhD

Date of Publication: 2010

“Boys with the Klinefelter syndrome may be sub-sufficient in androgen activity and require replacement therapy. That is controversial for the ‘mini’-puberty during the first few months of life. Whether androgen therapy will be helpful to boys between “mini” puberty and adolescence is being studied with the weak androgen, oxandrolone. Replacement starting in mid-puberty is required for most males with KS and important for the developmental of secondary sexual characteristics, and to permit the normal accrual of muscle mass, bone mineral content, adult regional distribution of body fat. Secondary goals of psychosocial development and both positive or negative behavioral effects of testosterone in KS need further study.”

Read more

New Oral Testosterone Drug

A group of people representing AXYS and the Klinefelter Syndrome community traveled to Washington,
DC in early January 2018 to provide public comments at an FDA hearing related to the approval of a new
oral testosterone drug called Jatenzo.

The Clarus drug company has developed this oral pill as an alternative for men that require testosterone
replacement therapy (TRT). Currently the only options for TRT involve the use of gels, patches, injections
or pellet implants. All of these options have different challenges and difficulties that can cause some
men to become frustrated and stop following their recommended replacement plan. This can lead to
multiple physical and emotional difficulties for some KS individuals. We believe an oral alternative would
be easier for many people and would help them start and continue their TRT programs.

Read more

2022-02-16T13:09:10-05:00Categories: 47,XXY (Klinefelter)|Tags: |

Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels

Article Title: Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels

Authors: Rebecca Vigen, Colin I. O’Donnell, Anna E. Barón, et al

Date of Publication: November 6, 2013

A November, 2013 article in JAMA pointed to increased heart risks for individuals on testosterone therapy.  Since many teens and men with XXY rely on testosterone therapy, we asked Dr. Wylie Hembree, previous member of AXYS’s Board of Directors, to put this article in perspective for those we serve.

Dr. Hembree’s comments:

“Over the years, the question of safety of testosterone treatment of men has been evaluated.  Appropriate diagnosis and treatment of men with testosterone has been well demonstrated in the two Endocrine Society Clinical Practice Guidelines and they have pointed out the risks as well as benefits. A few studies have demonstrated the vulnerability of older men – especially frail older men – to testosterone treatment.  All of us are very careful about treatment of testosterone deficient older men, especially those with hypertension, heart disease, prostate disease and diabetes. No one should be treated with testosterone without a complete evaluation that clearly demonstrates both clinical and laboratory evidence of testosterone deficiency and carefully assesses the risks of the treatment.  Careful monitoring thereafter is essential, especially in men with the above mentioned conditions and older men in general. There is no evidence that testosterone treatment is responsible for prostate cancer but in older men monitoring for prostate cancer is much more difficult.

Read more

2022-02-16T12:52:56-05:00Categories: 47,XXY (Klinefelter)|Tags: |

Hypogonadism in the Aging Male Diagnosis, Potential Benefits, and Risks of Testosterone Replacement Therapy

Article Title: Hypogonadism in the Aging Male Diagnosis, Potential Benefits, and Risks of Testosterone Replacement Therapy

Authors: Prasanth N. Surampudi, Christina Wang, and Ronald Swerdloff

Date of Publication: December 2011

Hypogonadism in older men is a syndrome characterized by low serum testosterone levels and clinical symptoms often seen in hypogonadal men of younger age. These symptoms include decreased libido, erectile dysfunction, decreased vitality, decreased muscle mass, increased adiposity, depressed mood, osteopenia, and osteoporosis. Hypogonadism is a common disorder in aging men with a significant percentage of men over 60 years of age having serum testosterone levels below the lower limits of young male adults.”

Read more

2022-02-16T12:52:30-05:00Categories: 47,XXY (Klinefelter)|Tags: |

Putting the ‘T’rouble in Testosterone Therapy?

Article Title: Putting the ‘T’rouble in Testosterone Therapy?

Author: Charles P. Vega, MD

Date of Publication: January 30, 2014

“Four in 5 men may have symptoms of testosterone deficiency, and testosterone replacement can improve body composition and metabolic outcomes related to serum glucose and cholesterol levels. In fact, some research even suggests that testosterone treatment might improve the risk for mortality among men with testosterone deficiency. However, a large new study finds a higher risk for cardiovascular disease or death associated with testosterone therapy, and it is not the first study to do so. The current review provides a balanced perspective regarding the challenging issue of testosterone deficiency and replacement among men.”

Read more (access to full article requires free Medscape registration)

2022-03-10T09:41:53-05:00Categories: 47,XXY (Klinefelter)|Tags: |
Go to Top